Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...

Oral squamous cell carcinoma (OSCC) is a leading cause of cancer-related deaths, and early detection is key to improving ...

Patients with primary Merkel cell carcinoma are at an increased risk of developing a secondary skin cancer vs other malignancies.

The intriguing VEGFxPD-1 bispecific antibody space gained oomph with phase III results disclosed April 23 by Akeso ...

Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in lung cancer trials.

in combination with chemotherapy as a first-line option for adults with a certain form of nasopharyngeal carcinoma.

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). FDA also approved penpulimab ...